News for Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tob

End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179 naïve participants , strengthening the case for a novel enrichment strategy, utilizing BRII-179 to identify and prime patients for improved functional cure outcomes 24 Week follow-up results from Cohorts 1-3 of the ENSURE study demonstrated sustained off-treatment benefits of elebsiran + PEG-IFNα combination therapy vs PEG-IFNα alone DURHAM, N.C. and BEIJING, May 8, 2025 /PRNewswire/ -- Brii Biosciences Limited ('Brii Bio' or the 'Company', stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced data from its ongoing Phase 2 ENSURE study as late-breaking posters at the European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam, the Netherlands.

Transaction Overview On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction involving Vir Biotechnology Inc. The firm reduced

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fir

**media[611481]**

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in c

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrati

VIR's T-cell engagers have potential in oncology and showed promise with initial data in January 2025. Read my thoughts about VIR's near-term catalysts.

Vir Biotechnology Inc's innovative approach to immunology positions it as a leader in combating infectious diseases and cancer.Strategic partnerships and fundi

R&D Expenses: $507 million in 2024, down from $580 million in 2023.G&A Expenses: $119 million in 2024, down from $174 million in 2023.Net Loss: $522 million in

Feb 26, 2025 / 09:30PM GMTOperator Hello. Welcome to VR Biotechnologies' 4th quarter and full year 2024 financial results and business update call. As a reminde

Vir Biotechnology (VIR) delivered earnings and revenue surprises of 10.59% and 15.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology Inc (VIR) has announced its financial results for the fourth quarter and full year ending December 31, 2024, alongside a corporate update. The

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31,

Revenue: $12.4 million for Q4 2024, surpassing the estimated $8.14 million.Earnings Per Share (EPS): $(0.76) for Q4 2024, better than the estimated $(0.87).Net

Vir Biotechnology Inc (VIR), a clinical-stage biopharmaceutical company, has announced that it will provide a corporate update and report its financial results

This is our list of the best health care stocks based on the highest return over the last 30 days.

**media[527277,527278]**